临床亚型与性别对中轴型脊柱关节炎一线生物制剂治疗停药的影響
这项回顾性队列研究纳入469例起始肿瘤坏死因子或白介素-17抑制剂的中轴型脊柱关节炎患者,评估亚型与性别对首次生物制剂停药的独立及交互效应。结果显示,非放射学中轴型脊柱关节炎(RR 1.80,95%CI 1.26-2.59)和女性(RR 1.49,95%CI 1.081-2.045)与停药显著相关;非放射学中轴型脊柱关节炎女性较放射学中轴型脊柱关节炎男性停药风险高(HR 2.30,95%CI 1.68-3.15,P<.001)。
要点
- 非放射学中轴型脊柱关节炎患者首次生物制剂停药风险显著高于放射学亚型(RR 1.80,95%CI 1.26-2.59)。
- 女性患者首次生物制剂停药风险显著高于男性(RR 1.49,95%CI 1.081-2.045)。
- 非放射学中轴型脊柱关节炎女性停药风险为放射学中轴型脊柱关节炎男性的2.30倍(HR 2.30,95%CI 1.68-3.15,P<.001)。
核心结论
- 非放射学中轴型脊柱关节炎和女性患者首次生物制剂停药风险显著更高、生物制剂生存期更短。
- 亚型与性别的联合效应呈升高趋势但未达统计学显著。
- 作者认为需关注女性非放射学中轴型脊柱关节炎患者潜在的治疗挑战。
研究设计与样本
- 回顾性队列研究,纳入469例起始肿瘤坏死因子或白介素-17抑制剂的非放射学与放射学中轴型脊柱关节炎患者。
- 采用改良泊松回归估计亚型与性别和停药关联的风险比(RR),并校正基线协变量。
- 采用相对超额风险(RERI)和风险比之比评估交互作用,并用Kaplan-Meier曲线分析生物制剂生存率。
主要发现
- 469例患者中64%停用首次生物制剂。
- 非放射学中轴型脊柱关节炎与停药显著相关(RR 1.80,95%CI 1.26-2.59)。
- 女性与停药显著相关(RR 1.49,95%CI 1.081-2.045)。
- 亚型与性别的相加交互RERI为0.49(95%CI -0.78至1.75),相乘交互RR比为1.05(95%CI 0.55-2.03),均未达统计学显著。
- 非放射学中轴型脊柱关节炎女性较放射学中轴型脊柱关节炎男性停药风险更高(HR 2.30,95%CI 1.68-3.15,P<.001);20年生物制剂生存率在非放射学亚型和女性患者中显著更低。
临床怎么用
- 原文未据此给出推荐。
- 作者指出这些发现强调需关注女性非放射学中轴型脊柱关节炎患者潜在的治疗挑战。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the main and interaction effects of axial spondyloarthritis (axSpA) subtype and sex on first biologic disease-modifying antirheumatic drug (bDMARD) discontinuation. METHODS: This retrospective cohort study included nonradiographic axSpA (nr-axSpA) and radiographic axSpA (r-axSpA) patients initiating tumour necrosis factor or interleukin-17 inhibitors. Modified Poisson regressions were used to estimate risk ratios (RRs) for the association of subtype and sex with discontinuation, adjusting for baseline covariates. Interaction was assessed using the relative excess risk due to interaction (RERI) and ratio of RRs. In addition, bDMARD survival rates were analysed using Kaplan-Meier curves. RESULTS: Among 469 patients, 64% discontinued their first bDMARD. Nr-axSpA (RR, 1.80; 95% CI, 1.26-2.59) and female sex (RR, 1.49; 95% CI, 1.081-2.045) were significantly associated with discontinuation. Positive interaction trends between subtype and sex were observed on additive (RERI 0.49, 95% CI, -0.78 to 1.75) and multiplicative (RR ratio, 1.05; 95% CI, 0.55-2.03) scales, though not statistically significant. Nr-axSpA females had twice the discontinuation risk of r-axSpA males (hazard ratio, 2.30; 95% CI, 1.68-3.15, P < .001). bDMARD survival over 20 years was significantly lower in nr-axSpA and female patients. CONCLUSIONS: Nr-axSpA and female patients face a significantly higher risk of bDMARD discontinuation and shorter bDMARD survival. Although the combined effect of subtype and sex trended higher, it was not statistically significant. These findings underscore the need to address potential treatment challenges in female nr-axSpA patients.
引用
- Remalante-Rayco P, Baja ES, Baskurt Z, et al. Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis. Ann Rheum Dis. 2025. PMID: 39919972. doi:10.1016/j.ard.2025.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。